Prof. Dr Christopher Twelves
Medical Oncology
Leeds University, United Kingdom
———————————————————————-
Professor Dr. Christopher Twelves is Professor of Clinical Cancer Pharmacology and Oncology and Director of the NIHR Leeds Clinical Research Facility.
He is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer.
After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre before taking up his current post at the University of Leeds and St James’s Institute of Oncology.
Professor Twelves has been a member of the Cancer Research UK New Agents Committee, Chair of the New Drug Development Group of the EORTC and was Scientific Chair of the Berlin 2009 ECCO-ESMO 34 meeting. He has been involved in the development of several important new agents including capecitabine, and eribulin. Professor Twelves has a particular interest in early clinical trials and pharmacokinetics including intra-tumoural drug pharmacokinetics.
Professor Twelves has published almost 300 papers in journals including the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and BMJ as well as spoking at numerous international meetings. He has also edited, or contributed to, several books including one on Phase I clinical trials and another on the design of Phase II clinical trials.
Note: Click [x] on top-right or anywhere on this pop-up to exit